Asian Journal of Urology最新文献

英文中文

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

The effects of the urotensin-II receptor antagonist palosuran treatment on the corpora cavernosa of streptozotocin-induced diabetic rats 尿促性素-II 受体拮抗剂帕洛苏兰对链脲佐菌素诱导的糖尿病大鼠海绵体的影响

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01 DOI: 10.1016/j.ajur.2024.02.010

Murat Olukman , Cenk Can , Sibel Ülker , Yiğit Uyanikgil , Türker Çavuşoğlu , Neslihan Düzenli , Deniz Coşkunsever , Fatma G. Kozcu

Objective

This study aimed to investigate the effects of treatment with palosuran, a urotensin receptor blocker, on molecular changes in the corpora cavernosa (CC) in diabetic rats.

Methods

Streptozotocin-induced diabetic rats were treated with palosuran 300 mg/kg per day for 6 weeks. Contraction of CC induced by potassium chloride, phenylephrine, and NG-nitro-L-arginine methyl ester and relaxation of CC induced by electrical field stimulation (EFS) and sodium nitroprusside (SNP) (endothelium-dependent and endothelium-independent stimuli, respectively), and Y-27632 (Rho-kinase inhibitor) were examined in organ baths. Direct contraction or relaxation induced by palosuran and urotensin-II (U-II) were also evaluated. The expression levels of nitric oxide synthetases (NOSs), RhoA, oxidative stress regulators, and U-II were analyzed by Western blotting or immunohistochemistry.

Results

Induction of diabetes in rats resulted in the decreased relaxant response to SNP, decreased pD₂ value of SNP, attenuated relaxant response to Y-27632 as well as the decreased RhoA expression in CC. Palosuran treatment of diabetic rats reversed all of these parameters; however, it further impaired the already weakened relaxation of diabetic CC in response to EFS. Although induction of diabetes did not change U-II expression in CC significantly, palosuran treatment reduced U-II expression in diabetic CC. The expression level of nNOS was lowered in diabetic CC; however, palosuran treatment did not change the decreased the neuronal NOS expression. In vitro exposure of diabetic CC strips to palosuran produced a direct relaxant response.

Conclusion

Palosuran treatment did not affect the expression of NOSs or reduce nitrergic conduction induced by EFS stimulation in diabetic CC. However, while directly triggering a relaxant response, it did not induce a prominent contraction either by decreasing U-II expression, or increasing the sensitivity of CC to nitric oxide which suggested that palosuran has the potential to support erectile function. Further and comprehensive studies are required to clarify this issue.

目的探讨尿紧张素受体阻滞剂palosuran对糖尿病大鼠海绵体（CC）分子变化的影响。方法采用帕洛舒兰300 mg/kg / d治疗链脲佐菌素诱导的糖尿病大鼠，连续6周。在器官浴中检测了氯化钾、苯肾上腺素和ng -硝基- l -精氨酸甲酯诱导的CC收缩和电场刺激（EFS）、硝普钠（SNP）（分别为内皮依赖性和内皮非依赖性刺激）和Y-27632 （rho激酶抑制剂）诱导的CC松弛。palosuran和urotensin-II （U-II）诱导的直接收缩或松弛也进行了评估。采用Western blotting或免疫组织化学方法分析一氧化氮合成酶（nos）、RhoA、氧化应激调节因子和U-II的表达水平。结果糖尿病诱导大鼠对SNP的舒张反应减弱，SNP的pD2值降低，Y-27632的舒张反应减弱，CC中RhoA的表达降低，而糖尿病大鼠给予帕洛舒兰治疗后这些参数均逆转；然而，它进一步损害了已经减弱的糖尿病CC对EFS的松弛。虽然诱导糖尿病没有显著改变CC中U-II的表达，但palosuran治疗降低了糖尿病CC中U-II的表达，降低了糖尿病CC中nNOS的表达水平；然而，帕络舒兰治疗未改变神经元NOS表达降低的情况。糖尿病CC条在体外暴露于palosuran产生直接松弛反应。结论palosuran治疗不影响糖尿病CC中NOSs的表达，也不降低EFS刺激引起的氮能传导，但直接引发松弛反应，但未通过降低U-II表达或增加CC对一氧化氮的敏感性引起明显收缩，提示palosuran具有支持勃起功能的潜力。需要进一步和全面的研究来澄清这个问题。

{"title":"The effects of the urotensin-II receptor antagonist palosuran treatment on the corpora cavernosa of streptozotocin-induced diabetic rats","authors":"Murat Olukman , Cenk Can , Sibel Ülker , Yiğit Uyanikgil , Türker Çavuşoğlu , Neslihan Düzenli , Deniz Coşkunsever , Fatma G. Kozcu","doi":"10.1016/j.ajur.2024.02.010","DOIUrl":"10.1016/j.ajur.2024.02.010","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the effects of treatment with palosuran, a urotensin receptor blocker, on molecular changes in the corpora cavernosa (CC) in diabetic rats.</div></div><div><h3>Methods</h3><div>Streptozotocin-induced diabetic rats were treated with palosuran 300 mg/kg per day for 6 weeks. Contraction of CC induced by potassium chloride, phenylephrine, and NG-nitro-<em>L</em>-arginine methyl ester and relaxation of CC induced by electrical field stimulation (EFS) and sodium nitroprusside (SNP) (endothelium-dependent and endothelium-independent stimuli, respectively), and Y-27632 (Rho-kinase inhibitor) were examined in organ baths. Direct contraction or relaxation induced by palosuran and urotensin-II (U-II) were also evaluated. The expression levels of nitric oxide synthetases (NOSs), RhoA, oxidative stress regulators, and U-II were analyzed by Western blotting or immunohistochemistry.</div></div><div><h3>Results</h3><div>Induction of diabetes in rats resulted in the decreased relaxant response to SNP, decreased pD<sub>2</sub> value of SNP, attenuated relaxant response to Y-27632 as well as the decreased RhoA expression in CC. Palosuran treatment of diabetic rats reversed all of these parameters; however, it further impaired the already weakened relaxation of diabetic CC in response to EFS. Although induction of diabetes did not change U-II expression in CC significantly, palosuran treatment reduced U-II expression in diabetic CC. The expression level of nNOS was lowered in diabetic CC; however, palosuran treatment did not change the decreased the neuronal NOS expression. <em>In vitro</em> exposure of diabetic CC strips to palosuran produced a direct relaxant response.</div></div><div><h3>Conclusion</h3><div>Palosuran treatment did not affect the expression of NOSs or reduce nitrergic conduction induced by EFS stimulation in diabetic CC. However, while directly triggering a relaxant response, it did not induce a prominent contraction either by decreasing U-II expression, or increasing the sensitivity of CC to nitric oxide which suggested that palosuran has the potential to support erectile function. Further and comprehensive studies are required to clarify this issue.</div></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"12 1","pages":"Pages 116-126"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141056925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improved outcomes of children with Wilms’ tumor in a low-middle-income nation: The contribution of a pediatric oncologist to successful management 在一个中低收入国家，改善了患有Wilms肿瘤的儿童的预后：儿科肿瘤学家对成功管理的贡献

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01 DOI: 10.1016/j.ajur.2024.04.008

Usama Al-Jumaily , Hamid D. Habeeb Rjeib , Mohammed Fawzi Alqanbar , Safa Faraj , Dheyaa Aldeen Al-Khateeb

Objective

The treatment of Wilms’ tumor (WT) in children largely relies on a multidisciplinary strategy. In the absence of an appropriate multidisciplinary team, we reviewed the data of children with WT to determine their outcomes. The primary goal of the study was to highlight the role that a pediatric oncologist plays in the management of WT in low- and middle-income countries, taking into account the variety of initial treatments available, the lack of multidisciplinary care, and management strategies to overcome obstacles.

Methods

Retrospective recruitment was used to identify patients, aged 18 years or under, with WT diagnosis, in a major tertiary hospital in Iraq between January 2014 and December 2021. Initially, patients were treated with a pretreatment biopsy, preoperative chemotherapy, or upfront nephrectomy.

Results

In this study, 54 patients were enrolled. The median age was 3.3 years. The numbers of patients with stages I and III are 24 (44%) and 12 (22%), respectively. Seven patients had pretreatment biopsies. In 23 patients, upfront nephrectomy was performed. The histology of only two patients was unfavorable. In 20 patients, intraoperative complications were not disclosed. The mean 3-year estimated event-free survival was 64% (standard deviation 6.6%) and the mean overall survival was 76% (standard deviation 6.8%). There was a significant statistical difference according to stages of disease (p<0.001). Compared with the extended study until December 2021, the overall survival of the previous study from January 2014 to December 2017 was only 40%.

Conclusion

Promising results for pediatric WT can be attained in low- and middle-income nations. Acquiring an evidence-based strategy tailored to a low- and middle-income country and a multidisciplinary approach may escalate the outcome.

目的儿童肾母细胞瘤（Wilms ' tumor， WT）的治疗在很大程度上依赖于多学科治疗策略。在缺乏适当的多学科团队的情况下，我们回顾了患有WT的儿童的数据，以确定他们的结果。该研究的主要目的是强调儿科肿瘤学家在低收入和中等收入国家WT管理中的作用，考虑到各种可用的初始治疗方法，缺乏多学科护理和克服障碍的管理策略。方法回顾性招募2014年1月至2021年12月在伊拉克一家大型三级医院诊断的年龄在18岁或以下的WT患者。最初，患者接受预处理活检、术前化疗或前期肾切除术。结果本研究共纳入54例患者。中位年龄为3.3岁。I期和III期患者分别为24例（44%）和12例（22%）。7例患者进行了预处理活检。23例患者行前期肾切除术。仅有2例患者的组织学表现为不良。20例患者术中并发症未披露。平均3年估计无事件生存率为64%（标准差6.6%），平均总生存率为76%（标准差6.8%）。不同疾病阶段间差异有统计学意义（p < 0.001）。与延长至2021年12月的研究相比，上一期研究2014年1月至2017年12月的总生存率仅为40%。结论在低收入和中等收入国家，儿童WT治疗可以取得令人满意的结果。获得针对低收入和中等收入国家的循证战略和多学科方法可能会使结果升级。

{"title":"Improved outcomes of children with Wilms’ tumor in a low-middle-income nation: The contribution of a pediatric oncologist to successful management","authors":"Usama Al-Jumaily , Hamid D. Habeeb Rjeib , Mohammed Fawzi Alqanbar , Safa Faraj , Dheyaa Aldeen Al-Khateeb","doi":"10.1016/j.ajur.2024.04.008","DOIUrl":"10.1016/j.ajur.2024.04.008","url":null,"abstract":"<div><h3>Objective</h3><div>The treatment of Wilms’ tumor (WT) in children largely relies on a multidisciplinary strategy. In the absence of an appropriate multidisciplinary team, we reviewed the data of children with WT to determine their outcomes. The primary goal of the study was to highlight the role that a pediatric oncologist plays in the management of WT in low- and middle-income countries, taking into account the variety of initial treatments available, the lack of multidisciplinary care, and management strategies to overcome obstacles.</div></div><div><h3>Methods</h3><div>Retrospective recruitment was used to identify patients, aged 18 years or under, with WT diagnosis, in a major tertiary hospital in Iraq between January 2014 and December 2021. Initially, patients were treated with a pretreatment biopsy, preoperative chemotherapy, or upfront nephrectomy.</div></div><div><h3>Results</h3><div>In this study, 54 patients were enrolled. The median age was 3.3 years. The numbers of patients with stages I and III are 24 (44%) and 12 (22%), respectively. Seven patients had pretreatment biopsies. In 23 patients, upfront nephrectomy was performed. The histology of only two patients was unfavorable. In 20 patients, intraoperative complications were not disclosed. The mean 3-year estimated event-free survival was 64% (standard deviation 6.6%) and the mean overall survival was 76% (standard deviation 6.8%). There was a significant statistical difference according to stages of disease (<em>p</em><0.001). Compared with the extended study until December 2021, the overall survival of the previous study from January 2014 to December 2017 was only 40%.</div></div><div><h3>Conclusion</h3><div>Promising results for pediatric WT can be attained in low- and middle-income nations. Acquiring an evidence-based strategy tailored to a low- and middle-income country and a multidisciplinary approach may escalate the outcome.</div></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"12 1","pages":"Pages 93-99"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology

Pub Date : 2025-01-01

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Asian Journal of Urology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀